Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting 216 enrolled Zhejiang Doer Biologics Co., Ltd.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors

Timeline

Start: 2023-11-27
Primary completion: 2027-07-30
Completion: 2027-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DR30206	Unknown	—	Intravenous

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

Summary

Timeline

Drugs

Indications